Pharma
MobiHealthNews spoke with Pear Therapeutics, Click Therapeutics and DTx newcomer Mahana Therapeutics to discuss whether in-licensing is the way to go for those just entering the space.
Also: Kaiser Permanente doubles down on the cloud with Accenture and Microsoft; Boehringer Ingelheim arms its reps with BreezoMeter's air quality data.
Machine learning applications are proliferating and improving, and this month we'll explore the many ways they're being put to work.
Flare Capital's Alexandra Mullin and Ian Chiang outline COVID-19's impact on the worsening opioid crisis and how the digital opioid use disorder space is likely to develop over the coming years.
Also: Blood glucose monitoring could be coming to next-gen consumer smartwatches; new incubator looking for disruptive health tech startups.
Asset Management Ventures' Skip Fleshman outlines COVID-19's impact on clinical trials and the resulting leap toward tech-enabled decentralized trials.
The pair will meet quarterly to discuss possible integrations and collaborations with the pharma industry.
This special collection, which will be updated throughout the month, looks at what's being done to ease the provider burden.
The results will not impact the current rollout of a new version of the app, under special FDA guidelines.
The research project will be conducted using the Apple Watch and iPhone, and is set to begin during 2021.